NEWS

 

MONTREAL, QC, Canada – September 15 th, 2015

Laurent Pharmaceuticals Inc. announced today that the LAU-7b program addressing aberrant inflammation is featured in the September 14th issue of BioCentury, one of the most widely read publications in the pharma industry. 

Published under the title “Balancing Act”, the article describes how Laurent Pharmaceuticals thinks its LAU-7b can carve out a niche in CF by correcting the inflammatory imbalance in CF patients and reduce lung deterioration over time, when given on top of standard of care.

Read the article

Events

Laurent Pharmaceuticals to participate at RESI on MaRS, April 10th 2018, Toronto, Canada

Laurent Pharmaceuticals to participate at the Biotech Showcase, January 8-10th 2018, San Francisco, CA, USA